Global biotechnology company BeiGene has commenced dosing patients in a new Phase II trial of its investigational anti-PD-1 antibody, BGB-A317, in patients with urothelial cancer (UC), more commonly known as bladder cancer, in China.

The single-arm, multi-centre trial seeks to investigate the efficacy and safety of BGB-A317 in patients with previously treated, PD-L1-positive, locally advanced or metastatic UC.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The trial’s primary endpoint includes the overall response rate (ORR) according to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST V1.1), as assessed by independent review.

Secondary endpoints of the study will feature ORR as assessed by investigators, duration of response, disease control rate, progression-free survival, overall survival, safety and tolerability.

BeiGenefounder, CEO and chairman John Oyler said: “It is estimated that the annual incidence of bladder cancer in China is between 55,000 and 80,000.

See Also:

“Chemotherapy-refractory bladder cancer patients in China have very limited treatment options and poor outcomes. This patient population is just one example of the unmet need for innovative cancer therapies, including PD-1 inhibitors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"It is estimated that the annual incidence of bladder cancer in China is between 55,000 and 80,000."

“For this reason, we are committed to developing BGB-A317 broadly and look forward to initiating additional registrational trials of this agent in China.”

China’s Fudan University Shanghai Cancer Centre professor Dingwei Ye is the lead principal investigator of the new Phase II trial.

BeiGene Immuno-Oncology chief medical officer Amy Peterson said: “This trial will examine BGB-A317’s efficacy and safety in patients with PD-L1-expressing bladder cancer, who we believe may be more likely to benefit from a PD-1 inhibitor.

“We plan to expand the development programme for BGB-A317 in China and other geographies, both as monotherapy and in combination.”

In addition, BGB-A317 is currently being evaluated in a trial in China in patients with relapsed or refractory classical Hodgkin lymphoma.